Clinical Trial Update: A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS) [Phase 3]

View source ↗

Summary

A Phase 3 study comparing Rebif and Avonex for relapsing-remitting multiple sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis Relapsing-remitting

Drugs mentioned

• Avonex (Interferon beta-1a)
• Rebif (interferon beta-1a)

Snippet

Sponsor: EMD Serono | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Status: COMPLETED